Zacks Research Has Bullish Estimate for BHC Q2 Earnings

Bausch Health Companies Inc. (NYSE:BHCFree Report) – Stock analysts at Zacks Research increased their Q2 2025 earnings estimates for Bausch Health Companies in a research report issued on Tuesday, March 11th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $1.05 for the quarter, up from their previous forecast of $1.04. The consensus estimate for Bausch Health Companies’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2026 earnings at $1.24 EPS, FY2026 earnings at $4.72 EPS and FY2027 earnings at $5.67 EPS.

Other analysts have also recently issued research reports about the stock. Royal Bank of Canada reduced their target price on shares of Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating on the stock in a report on Thursday, January 30th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $7.42.

Check Out Our Latest Stock Analysis on Bausch Health Companies

Bausch Health Companies Stock Performance

Shares of BHC opened at $6.79 on Thursday. The stock has a market capitalization of $2.50 billion, a PE ratio of -56.54, a P/E/G ratio of 0.37 and a beta of 0.59. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46. The company’s 50-day simple moving average is $7.27 and its 200-day simple moving average is $7.65.

Bausch Health Companies (NYSE:BHCGet Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). The business had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%.

Hedge Funds Weigh In On Bausch Health Companies

Several hedge funds have recently added to or reduced their stakes in BHC. Mountain Hill Investment Partners Corp. purchased a new position in shares of Bausch Health Companies during the fourth quarter worth approximately $56,000. Bank of Nova Scotia purchased a new position in shares of Bausch Health Companies during the fourth quarter worth approximately $83,000. One68 Global Capital LLC purchased a new position in shares of Bausch Health Companies during the fourth quarter worth approximately $90,000. Balyasny Asset Management L.P. purchased a new position in shares of Bausch Health Companies during the fourth quarter worth approximately $97,000. Finally, Alpine Global Management LLC purchased a new position in shares of Bausch Health Companies during the fourth quarter worth approximately $114,000. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

Bausch Health Companies Company Profile

(Get Free Report)

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

See Also

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.